US equities
|
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
MU
$1,029.00
▼-0.66%
NVDA
$229.28
▼-0.52%
SPCX
$162.57
▲+1.25%
TSLA
$382.70
▲+2.05%
AAPL
$336.64
▼-1.11%
MSFT
$535.07
▲+2.38%
AMZN
$262.43
▲+3.29%
META
$718.67
▼-0.31%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
InVivo Therapeutics Holdings Corp. - Common Stock
(NQ:
NVIV
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about InVivo Therapeutics Holdings Corp. - Common Stock
InVivo Therapeutics Announces Topline Data from Pivotal INSPIRE 2.0 Study in Acute Spinal Cord Injury
March 09, 2023
From
InVivo Therapeutics Holdings Corp.
Via
Business Wire
InVivo Therapeutics Announces Closing of $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
October 11, 2022
From
InVivo Therapeutics Holdings Corp.
Via
Business Wire
InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules
October 07, 2022
From
InVivo Therapeutics Holdings Corp.
Via
Business Wire
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment Conference
September 09, 2022
From
InVivo Therapeutics Holdings Corp.
Via
Business Wire
InVivo Therapeutics Announces Appointment of Heather M. Hamel as Chief Legal Officer and General Counsel
July 13, 2022
From
InVivo Therapeutics Holdings Corp.
Via
Business Wire
InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery
June 08, 2022
From
InVivo Therapeutics Holdings Corp.
Via
Business Wire
InVivo Therapeutics Announces Completion of Enrollment for the INSPIRE 2.0 Acute Spinal Cord Injury Study
June 02, 2022
From
InVivo Therapeutics Holdings Corp.
Via
Business Wire
InVivo Therapeutics Announces Reverse Stock Split
April 14, 2022
From
InVivo Therapeutics Holdings Corp.
Via
Business Wire
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright BioConnect Conference
January 06, 2022
From
InVivo Therapeutics Holdings Corp.
Via
Business Wire
InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference
September 09, 2021
From
InVivo Therapeutics Holdings Corp.
Via
Business Wire
InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study
September 08, 2021
From
InVivo Therapeutics Holdings Corp.
Via
Business Wire
InVivo Therapeutics Announces FDA Acceptance of Preclinical Module in Support of Company’s Complete HDE Submission
July 13, 2021
From
InVivo Therapeutics Holdings Corp.
Via
Business Wire
InVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021
July 06, 2021
From
InVivo Therapeutics Holdings Corp.
Via
Business Wire
